Doxazosin Tablet
Product Images NDC 82804-087

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 82804-087). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

82804-087-30 (Doxazosin 4mg 100)

This text provides detailed information about a medication named Doxazosin 4mg. Each tablet contains doxazosin mesylate equivalent to 4 mg doxazosin. The tablets are white to off-white, capsule-shaped, scored, imprinted with "APO" on one side and "095" with a partial bisect on the other. The medication is manufactured by Apotex Inc. in Toronto, Canada. It is recommended to store the tablets at 20°-25°C (68°-77°F) and keep them out of the reach of children. The medication is packaged by Proficient Rx LP in Thousand Oaks, CA. Lot numbers and expiration dates are provided.*

FDA Label Image

Doxazosin-structure.jpg (Doxazosin Structure)

FDA Label Image

Figure1.jpg (Figure1)

This is a statistical comparison showing the mean change in total symptom score from baseline and the mean increase in maximum urinary flow rate (mL/sec) from baseline. The duration of treatment in weeks is also displayed. The results indicate significance compared to placebo and baseline. Doxazosin was titrated up to a maximum dose of 8 mg during the study.*

FDA Label Image

Table3.jpg (Table3)

This is a summary of effectiveness data from placebo-controlled trials evaluating the maximum flow rate and symptom scores in patients receiving doxazosin for benign prostatic hyperplasia (BPH). The data includes baseline values and changes in flow rate and symptom scores for different doses of doxazosin compared to placebo. The studies were conducted over different periods, with variations in dose titration. The AUA questionnaire and Modified Boyarsky Questionnaire were used to evaluate symptoms. The results suggest that doxazosin has a positive effect on symptoms and flow rate in patients with BPH.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.